Dr. Shannon Miller is the Vice President of Operations at Inimmune. She completed her PhD in Immunology at the University of Colorado and then completed a postdoc at the University of Montana. Dr Miller held a faculty position at UM and served as an Investigator and Director of Immunology at Inimmune prior to her role as VP of Operations.
CHRONIC DISEASE, AUTOIMMUNITY & THE VIROMERoom 204C
Exploring the drivers and development of vaccines against non-infectious disease targets.
10am Chair’s opening remarks: Please introduce yourself and give a brief overview of the sessions to be covered throughout the day before introducing the speakers on stage for the opening panel.Dr Michael Caldwell, Assoc VP Vaccine Research & Education, Meharry Medical College
10:05am Panel: Adjuvants and Immunity: Exploring Systemic Benefits Beyond Zoster- Beyond Shingles: Explore emerging data linking zoster vaccines to reduced risks of cardiovascular disease and Alzheimer’s.- Immunological Insights: Discuss how zoster vaccines adjuvant systems may drive systemic immune benefits beyond zoster prevention- Correlates of Protection: Identify immune markers that may explain long-term protection and -potential cross-disease benefits.- Public Health Implications: Debate whether zoster vaccines should be recommended earlier in life for chronic disease prevention.- Future Research: Outline next steps for validating these findings and applying the model to other latent viruses like EBV.Moderator: Jay Evans, Chief Scientific and Strategy Officer, InimmuneDr Bali Pulendran, Professor, Director, Institute for Immunity, Transplantation and Infection, Stanford University School of MedicineDr Ofer Levy, Director, Precision Vaccines Program, Division of Infectious Diseases, Boston Children’s Hospital, Professor, Harvard Medical School Dr Pascal Geldsetzer, Assistant Professor of Medicine, Stanford UniversityDr Ken J. Ishii, Director and Professor, International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo
11:00 Uncovering the Immune Landscape of Autoimmune Disease: From Parkinsons to ALSDr Emil Johansson, Senior Scientist, Neurodegeneration Program Lead, La Jolla Institute for Immunology
11:30 The shingles vaccine and dementia: A causal relationship?Dr Pascal Geldsetzer, Assistant Professor of Medicine, Stanford University
12:00 Clinical Development of a TLR4 Agonist in Phase 2 Trials for Allergic RhinitisDr Shannon Miller, VP of Operations, Inimmune
12:30 Accelerating Development of Vaccines for Prevention and Control of Alzheimer’s Disease: The Alzheimer’s Vaccine InitiativeTed Schenkelberg, Managing Partner, Next Frontier Advisors